Adagene Inc. (ADAG)

2,1200 -0,0700 (-3,20 %) À la clôture : 04:00PM EDT

Adagene Inc.

Building C14
4th Floor No. 218, Xinghu Street Suzhou Industrial Park
Suzhou 215123
China
86 512 8777 3632
https://www.adagene.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 174

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Peter P. Luo Ph.D.	Co- Founder, Chairman, CEO and President of R&D	S.O.	S.O.	1966
Mr. Man Kin Tam M.B.A.	CFO & Director	S.O.	S.O.	1977
Dr. Jc Xu M.D., Ph.D.	Chief Scientific Officer	S.O.	S.O.	1965
Ms. Ami Celeste Knoefler	Vice President of Investor Relations & Corporate Communications	S.O.	S.O.	S.O.
Ms. Ling Zhou	Head of Human Resources	S.O.	S.O.	S.O.
Dr. Qinghai Zhao	Chief Manufacturing Officer	S.O.	S.O.	1961
Ms. Yan Li M.B.A.	Senior VP of Bioinformatics & Information Technology and Director	S.O.	S.O.	1975
Ms. Xiaohong She	Senior VP & Head of Clinical Operations	S.O.	S.O.	1967
Dr. Guizhong Liu Ph.D.	Senior Vice President of Early Drug Discovery	S.O.	S.O.	1971
Mr. Alexander Goergen	VP & Head of Business Development	S.O.	S.O.	1987

Les montants ont été établis en date du et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Adagene Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.